Planet Innovation is redefining what it means to be a strategic investor by providing investee companies with not just funding, but access to its people, facilities and networks.
Lumos Diagnostics, a PI investee company, has been admitted to the Australian Securities Exchange (ASX) with trading commencing on July 5 after raising $63 million AUD in an Initial Public Offering (IPO).
Planet Innovation and Lumos Diagnostics have won two awards at the 2020 Good Design Awards, including a Good Design Award Gold accolade for Lumos’s Leelu Reader.
We are seeking GPs and other healthcare professionals in Victoria, Australia to pilot a new TGA-approved point-of-care test to help differentiate patients with viral from bacterial acute respiratory tract infections.
November 18-24 is World Antibiotic Awareness Week, so it’s a good time to draw attention to the global health challenge of antibiotic resistance, which Planet Innovation is combating through its business Lumos Diagnostics.
Journalist Virginia Trioli spoke to Planet Innovation co-CEO and co-founder Stuart Elliott live on ABC Radio about the challenges the company has faced and the successes we have enjoyed.
Lumos Diagnostics and RPS Diagnostics have merged to create a full-service point-of-care diagnostic development company and support the international commercialization of FebriDx.
Lumos Diagnostics is expanding its global footprint after agreeing an ongoing manufacturing deal for a customized lateral flow reader with a California-based life sciences company.
A roundup of the latest news and opinions from PI.
Lumos Diagnostics develops custom products for its partners using a unique combination of integrated assay and engineering capability paired with its proven reader optical technologies.
Planet Innovation’s PoC (Point-of-Care) diagnostic platform, Nplex, will benefit from further investment to develop a cloud-connected medical counter-measures device, for the rapid detection of infectious diseases.